PhD position in the MSCA-DN “CanGoNano”

PhD Position in the MSCA Doctoral Network “CanGoNano” - Glyconanomaterials for the Delivery of Peptide Antigens or mRNA in Breast Cancer Models: Formulation and Anti-Cancer Efficacy

CanGoNano is a European Doctoral Network funded under the Horizon Europe Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA-DN) programme. The network focuses on the development of glyconanomaterials (GNMs) as precision tools to advance our understanding of antigen-presenting cell (APC) activation against cancer through the delivery of antigenic peptides and mRNAs encoding these peptides.

Within the CanGoNano consortium, the Universidad Internacional de La Rioja (UNIR) is recruiting one Doctoral Candidate (DC14) to undertake research on the development of glyconanomaterials for the delivery of peptide antigens or mRNA in breast cancer models.

The selected candidate will become part of the CanGoNano Doctoral Network, benefiting from a unique international research and training environment that brings together leading academic institutions, research centres and industrial partners across Europe.

• A 36-month full-time employment contract funded by the Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA-DN) programme.

• Competitive salary and employment conditions in accordance with the MSCA regulations and the host institution's policies.

• Enrolment in the PhD Programme in Molecular Biosciences at the Universidad Autónoma de Madrid.

• Personalised scientific supervision by internationally recognised experts in glycoscience, nanotechnology and cancer immunotherapy.

• Access to state-of-the-art research facilities and multidisciplinary expertise at UNIR, UAM and partner institutions.

• International mobility through planned secondments at leading European research organisations and biotechnology companies.

• A structured training programme covering both scientific and transferable skills, including innovation, communication, entrepreneurship, research management and career development.

• An inclusive, collaborative and multidisciplinary research environment committed to excellence in doctoral training.

36 months, starting on 15 February 2027.

The candidate will be based in Madrid and Logroño (Spain) and will join the MEDONLINE Research Group at UNIR: https://investigacion.unir.net/grupos/35492/detalle and the Centro de Biología Molecular Severo Ochoa (CBMSO-UAM: https://www.uam.es/uam/investigacion/grupos-de-investigacion/detalle/f1-95

Universidad Internacional de La Rioja (UNIR), Spain https://www.unir.net

• Prof. Carmen Álvarez-Domínguez, Universidad Internacional de La Rioja (UNIR), Spain

https://www.researchgate.net/profile/Carmen-Alvarez-Dominguez

• Prof. Nuria Gironés Pujol, Universidad Autónoma de Madrid (UAM), Spain

https://www.researchgate.net/profile/Nuria-Girones

• Dr. Jürgen Mairhofer, EnGenes Biotech GmbH (Austria)

Further information about the CanGoNano Doctoral Network: https://euraxess.ec.europa.eu/jobs/448431 and the application process is available at: https://cangonano.eu/

This PhD project will focus on:

• Characterization and transfection of HER2 breast cancer cell lines.

• Set up of the doses of breast-transfected cell lines, kinetics of tumour progression and immune responses in vivo.

• Evaluation of GNM formulations (including or not adjuvants) and doses to activate immune organs in vivo.

• Examine the capacity of GNM as breast cancer immunotherapies: prophylactic vs therapeutic effects.

• Training in GNM assembly & formulation, anti-cancer immunotherapy, establishing breast cancer in mice, bionanotech, biointeractions.

The Doctoral Candidate will benefit from international secondments within the CanGoNano consortium:

• CNRS (France) – Prof. Catherine Menard-Moyon (Year 2, 1 month): training in the synthesis of amino acid-based nanoparticles (AA-NPs).

• EnGenes Biotech GmbH (Austria) – Dr. Jürgen Mairhofer (Year 3, 1 month): training in lectin expression technologies.

The selected candidate will be enrolled in the PhD Programme in Molecular Biosciences at the Universidad Autónoma de Madrid (UAM), Spain.

https://www.uam.es/EscuelaDoctorado/(en_GB)-Programa-Doctorado_Biociencias_Moleculares/1446833580304.htm

The EDUCATIVO Group is firmly committed to equal opportunities and diversity, thereby creating an environment free from all discrimination.

UNIVERSIDAD INTERNACIONAL DE LA RIOJA, S.A.U. (hereinafter, "UNIR"), as an entity belonging to the PROEDUCA Group, will process the personal data you have provided in order to: manage your participation in selection processes, assess your profile and, if it fits other vacancies, share it with other companies in the Group.

The detailed information about the processing of your personal data is available in the legal text accompanying the registration form. You may revoke the consent given, as well as exercise the rights recognized in Articles 15 to 22 of Regulation (EU) 2016/679, by request addressed to Av. de la Paz, 137, 26006, Logroño, or to the following email address [email protected]. If you wish, you can consult additional and detailed information about data protection at the following link.

PhD Position in the MSCA Doctoral Network “CanGoNano” - Glyconanomaterials for the Delivery of Peptide Antigens or mRNA in Breast Cancer Models: Formulation and Anti-Cancer Efficacy

CanGoNano is a European Doctoral Network funded under the Horizon Europe Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA-DN) programme. The network focuses on the development of glyconanomaterials (GNMs) as precision tools to advance our understanding of antigen-presenting cell (APC) activation against cancer through the delivery of antigenic peptides and mRNAs encoding these peptides.

Within the CanGoNano consortium, the Universidad Internacional de La Rioja (UNIR) is recruiting one Doctoral Candidate (DC14) to undertake research on the development of glyconanomaterials for the delivery of peptide antigens or mRNA in breast cancer models.

The selected candidate will become part of the CanGoNano Doctoral Network, benefiting from a unique international research and training environment that brings together leading academic institutions, research centres and industrial partners across Europe.

• A 36-month full-time employment contract funded by the Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA-DN) programme.

• Competitive salary and employment conditions in accordance with the MSCA regulations and the host institution's policies.

• Enrolment in the PhD Programme in Molecular Biosciences at the Universidad Autónoma de Madrid.

• Personalised scientific supervision by internationally recognised experts in glycoscience, nanotechnology and cancer immunotherapy.

• Access to state-of-the-art research facilities and multidisciplinary expertise at UNIR, UAM and partner institutions.

• International mobility through planned secondments at leading European research organisations and biotechnology companies.

• A structured training programme covering both scientific and transferable skills, including innovation, communication, entrepreneurship, research management and career development.

• An inclusive, collaborative and multidisciplinary research environment committed to excellence in doctoral training.

36 months, starting on 15 February 2027.

The candidate will be based in Madrid and Logroño (Spain) and will join the MEDONLINE Research Group at UNIR: https://investigacion.unir.net/grupos/35492/detalle and the Centro de Biología Molecular Severo Ochoa (CBMSO-UAM: https://www.uam.es/uam/investigacion/grupos-de-investigacion/detalle/f1-95

Universidad Internacional de La Rioja (UNIR), Spain https://www.unir.net

• Prof. Carmen Álvarez-Domínguez, Universidad Internacional de La Rioja (UNIR), Spain

https://www.researchgate.net/profile/Carmen-Alvarez-Dominguez

• Prof. Nuria Gironés Pujol, Universidad Autónoma de Madrid (UAM), Spain

https://www.researchgate.net/profile/Nuria-Girones

• Dr. Jürgen Mairhofer, EnGenes Biotech GmbH (Austria)

Further information about the CanGoNano Doctoral Network: https://euraxess.ec.europa.eu/jobs/448431 and the application process is available at: https://cangonano.eu/

This PhD project will focus on:

• Characterization and transfection of HER2 breast cancer cell lines.

• Set up of the doses of breast-transfected cell lines, kinetics of tumour progression and immune responses in vivo.

• Evaluation of GNM formulations (including or not adjuvants) and doses to activate immune organs in vivo.

• Examine the capacity of GNM as breast cancer immunotherapies: prophylactic vs therapeutic effects.

• Training in GNM assembly & formulation, anti-cancer immunotherapy, establishing breast cancer in mice, bionanotech, biointeractions.

The Doctoral Candidate will benefit from international secondments within the CanGoNano consortium:

• CNRS (France) – Prof. Catherine Menard-Moyon (Year 2, 1 month): training in the synthesis of amino acid-based nanoparticles (AA-NPs).

• EnGenes Biotech GmbH (Austria) – Dr. Jürgen Mairhofer (Year 3, 1 month): training in lectin expression technologies.

The selected candidate will be enrolled in the PhD Programme in Molecular Biosciences at the Universidad Autónoma de Madrid (UAM), Spain.

https://www.uam.es/EscuelaDoctorado/(en_GB)-Programa-Doctorado_Biociencias_Moleculares/1446833580304.htm

El Grupo EDUCATIVO está firmemente comprometido con la igualdad de oportunidades y la diversidad, logrando con ello crear un entorno libre de toda discriminación.

UNIVERSIDAD INTERNACIONAL DE LA RIOJA, S.A.U. (en adelante, "UNIR"), como entidad integrante del Grupo PROEDUCA, tratará los datos de carácter personal que usted ha proporcionado con la finalidad de: gestionar tu participación en procesos de selección, valorar tu perfil y, si encaja con otras vacantes, compartirlo con otras empresas del Grupo.

La información detallada sobre el tratamiento de tus datos personales está disponible en el texto legal que acompaña al formulario de inscripción. Usted podrá revocar el consentimiento otorgado, así como ejercitar los derechos reconocidos en los artículos 15 a 22 del Reglamento (UE) 2016/679, mediante solicitud dirigida en Av. de la Paz, 137, 26006, Logroño, o a la siguiente dirección de correo electrónico [email protected], identificándose debidamente. Si lo desea, puede consultar información adicional y detallada sobre protección de datos en el siguiente enlace.